Cargando…

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen

BACKGROUND: Factor XI (FXI) is a promising target for novel anticoagulants because it shows a strong relation to thromboembolic diseases, while fulfilling a mostly supportive role in hemostasis. Anticoagulants targeting FXI could therefore reduce the risk for thrombosis, without increasing the chanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bar Barroeta, Awital, Marquart, J. Arnoud, Bakhtiari, Kamran, Meijer, Alexander B., Urbanus, Rolf T., Meijers, Joost C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795894/ https://www.ncbi.nlm.nih.gov/pubmed/35815349 http://dx.doi.org/10.1111/jth.15815

Ejemplares similares

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
por: Li, Chan, et al.
Publicado: (2019)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study
por: Handa, Shivani, et al.
Publicado: (2022)

Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo
por: Chen, Zu-Lin, et al.
Publicado: (2022)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Differences in wild-type– and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies
por: Foley, Jonathan H., et al.
Publicado: (2022)

Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation
por: Shim, Young Jun, et al.
Publicado: (2021)

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex
por: Gierula, Magdalena, et al.
Publicado: (2019)

Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library
por: Sim, Derek S., et al.
Publicado: (2023)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Factor VIII as a potential player in cancer pathophysiology
por: Walker, Gillian E., et al.
Publicado: (2022)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
por: Dhami, Sukhraj Pal Singh, et al.
Publicado: (2022)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Mapping the prothrombin-binding site of pseutarin C by site-directed PEGylation
por: Üstok, Fatma Işık, et al.
Publicado: (2022)

The binding of autotaxin to integrins mediates hyperhomocysteinemia-potentiated platelet activation and thrombosis in mice and humans
por: Han, Lulu, et al.
Publicado: (2021)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets
Publicado: (1989)

CD44–fibrinogen binding promotes bleeding in acute promyelocytic leukemia by in situ fibrin(ogen) deposition
por: Wang, Chunxu, et al.
Publicado: (2022)

Platelet binding to polymerizing fibrin is avidity driven and requires activated αIIbβ3 but not fibrin cross-linking
por: Buitrago, Lorena, et al.
Publicado: (2021)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

The Role of Copper (II) on Kininogen Binding to Tropomyosin in the Presence of a Histidine–Proline-Rich Peptide
por: Santoro, Anna Maria, et al.
Publicado: (2020)

Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains
por: Shamanaev, Aleksandr, et al.
Publicado: (2022)

Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type-1 diabetes
por: Merchant, Michael L., et al.
Publicado: (2013)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ftvs1hgdoi8ilovs0csu98nj74